181 related articles for article (PubMed ID: 29185289)
61. Hypocalcaemia following thyroidectomy unresponsive to oral therapy.
Etheridge ZC; Schofield C; Prinsloo PJ; Sturrock ND
Hormones (Athens); 2014; 13(2):286-9. PubMed ID: 24776629
[TBL] [Abstract][Full Text] [Related]
62. Questions and facts regarding denosumab discontinuation among postmenopausal women.
Makras P; Anastasilakis AD
Expert Opin Drug Saf; 2021 May; 20(5):499-501. PubMed ID: 33372551
[No Abstract] [Full Text] [Related]
63. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
Uhm SJ; Hall JA; Herrington JD
J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
[TBL] [Abstract][Full Text] [Related]
64. [Denosumab--a new efficient osteoporosis therapy].
Rejnmark L; Vestergaard P; Mosekilde L
Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
[TBL] [Abstract][Full Text] [Related]
65. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
66. Acute blepharitis: an unusual complication of zoledronic acid.
Osta LE; Osta BE
Int J Rheum Dis; 2017 Apr; 20(4):515-518. PubMed ID: 26412501
[No Abstract] [Full Text] [Related]
67. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
68. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
[TBL] [Abstract][Full Text] [Related]
69. A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.
Blackley S; Anderson K; Berg J
J R Coll Physicians Edinb; 2015; 45(2):133-5. PubMed ID: 26181529
[TBL] [Abstract][Full Text] [Related]
70. Effect of denosumab on bone mineral density in a postmenopausal osteoporotic woman with prolonged chronic mild hyponatremia.
Fujishima R; Ushimaru S; Sumi H; Aso M; Akaike T; Shiizaki K; Tominaga N
Osteoporos Int; 2023 Dec; 34(12):2139-2140. PubMed ID: 37723308
[No Abstract] [Full Text] [Related]
71. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
72. Hypoparathyroidism unmasked by alendronate.
Kashyap AS; Kashyap S
Postgrad Med J; 2000 Jul; 76(897):417-8. PubMed ID: 10878202
[TBL] [Abstract][Full Text] [Related]
73. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.
Cowan A; Jeyakumar N; McArthur E; Fleet JL; Kanagalingam T; Karp I; Khan T; Muanda FT; Nash DM; Silver SA; Thain J; Weir MA; Garg AX; Clemens KK
J Bone Miner Res; 2023 May; 38(5):650-658. PubMed ID: 36970786
[TBL] [Abstract][Full Text] [Related]
74. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
[TBL] [Abstract][Full Text] [Related]
75. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
[TBL] [Abstract][Full Text] [Related]
76. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
Lewiecki EM
Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
[TBL] [Abstract][Full Text] [Related]
77. Denosumab for treatment of postmenopausal osteoporosis.
Chitre M; Shechter D; Grauer A
Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
[TBL] [Abstract][Full Text] [Related]
78. Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function.
Kostine M; Mehsen-Cetre N; Bannwarth B
Therapie; 2017 Jun; 72(3):383-385. PubMed ID: 27745697
[No Abstract] [Full Text] [Related]
79. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?
Tsvetov G; Amitai O; Shochat T; Shimon I; Akirov A; Diker-Cohen T
Osteoporos Int; 2020 Apr; 31(4):655-665. PubMed ID: 31838550
[TBL] [Abstract][Full Text] [Related]
80. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
